Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: A pilot study

Fertility and Sterility

Volumn 75, Issue 1, 2001, Pages 46-52

  Glueck, C J ^a   Phillips, Harvey ^a   Cameron, Dan ^a   Sieve Smith, Luann ^a   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

Author keywords

Metformin; Polycystic ovary syndrome; Pregnancy; Teratogenicity

Indexed keywords

METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ECHOGRAPHY; FEMALE; FETUS DEVELOPMENT; HUMAN; INSULIN BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRIORITY JOURNAL; SPONTANEOUS ABORTION;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ADULT; BIRTH WEIGHT; FEMALE; HEALTH STATUS INDICATORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; OLIGOMENORRHEA; PILOT PROJECTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN INACTIVATORS; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY TRIMESTER, FIRST; SERINE PROTEINASE INHIBITORS;

EID: 0035168622     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(00)01666-6     Document Type: Article

References (30)

1. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with polycystic ovary syndrome
2. Plasminogen activator inhibitor activity; an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome
3. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome
4. The plasminogen activator system in women with polycystic ovary syndrome
5. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) in lean women with and without the polycystic ovary syndrome
6. The importance of diagnosing the polycystic ovary syndrome
7. Raised plasminogen activator inhibitor (PAI-1) is not an independent risk factor in the polycystic ovary syndrome
8. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) study
9. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology
10. Anti-activator inhibitors of plasminogen
11. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
12. Metformin throughout pregnancy in women with polycystic ovary syndrome reduces first trimester miscarriage from 45% to 5%
13. Hypofibrinolysis and hyperandrogenemia; risk factors for pregnancy failure in polycystic ovary syndrome
14. Oral hypoglycaemics in the first trimester and fetal outcome
15. Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Grote Schuur Hospital
16. Metformin in management of pregnant insulin-dependent diabetics
17. Side-effects of metformin
18. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
19. Antepartum testing
20. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 levels in children and adults
21. Clinical assessment of body hair growth in women
22. Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 239 hyperlipidemia patients
23. The 4G/4G polymorphism of the hypofibrinolytic PAI-1 gene; an independent risk factor for serious pregnancy complications
24. Increased frequency of genetic thrombophilia in women with complications of pregnancy
25. Thrombophilia-associated pregnancy wasteage